Group 1 - The core point of the news is that Proprius (Shanghai) Pharmaceutical Technology Development Co., Ltd. experienced a stock decline of 5.07%, with a current share price of 45.51 yuan and a total market capitalization of 3.596 billion yuan [1] - Proprius was established on February 22, 2013, and went public on May 17, 2022, focusing on technology development, transfer, consulting, and services in the pharmaceutical sector, with 100% of its revenue coming from services [1] Group 2 - Morgan Stanley's fund holds a significant position in Proprius, with the "Morgan Stanley Youyue Anhe Mixed A" fund owning 80,300 shares, representing 6.23% of the fund's net value, making it the fourth-largest holding [2] - The fund has reported a floating loss of approximately 195,100 yuan as of the latest update [2] - The fund manager, Zhao Weijie, has been in charge for 4 years and 260 days, with the fund's total asset size at 339 million yuan, achieving a best return of 30.95% and a worst return of -32.57% during his tenure [2]
普蕊斯股价跌5.07%，摩根士丹利基金旗下1只基金重仓，持有8.03万股浮亏损失19.51万元